Stereotactic radiotherapy for wet age-related macular degeneration:Current perspectives by Neffendorf, James E & Jackson, Timothy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.2147/OPTH.S75638
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Neffendorf, J. E., & Jackson, T. (2015). Stereotactic radiotherapy for wet age-related macular degeneration:
Current perspectives. Clinical ophthalmology (Auckland, N.Z.), 9, 1829-1834. 10.2147/OPTH.S75638
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
© 2015 Neffendorf and Jackson. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) 
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Clinical Ophthalmology 2015:9 1829–1834
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1829
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S75638
Stereotactic radiotherapy for wet age-related 
macular degeneration: current perspectives
James e Neffendorf
Timothy L Jackson
Department of Ophthalmology, 
School of Medicine, King’s College 
London, London, United Kingdom
Abstract: Neovascular age-related macular degeneration is a leading cause of blindness in 
the developed world. Currently, the treatment of choice is intravitreal injections of anti-VEGF 
medications. These require frequent dosing, up to monthly, and impose a substantial burden 
on patients and the health economy. Ionizing radiation was proposed as a possible treatment 
for age-related macular degeneration due to its anti-inflammatory and anti-fibrotic properties. 
Stereotactic radiotherapy is an outpatient-based radiotherapy platform that provides stereotactic 
application of low energy X-ray to the retina in three highly collimated beams that cross the 
inferior sclera to overlap at the macula. A randomized, double-masked, sham-controlled trial of 
230 patients (INTREPID) showed that a single dose of stereotactic radiotherapy significantly 
reduces the number of intravitreal anti-VEGF injections needed over 2 years. A larger random-
ized controlled trial (STAR) is underway.
Keywords: wet age-related macular degeneration, radiation therapy, stereotactic radiotherapy, 
vascular endothelial growth factor
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in 
individuals over 50 years old in developed nations.1,2 It can have a profound impact 
on quality of life, and affects more than 500,000 people in the UK alone.3 Approxi-
mately 10% of those affected have the neovascular “wet” form of the disease, which 
is clinically more aggressive and destructive, but also more amenable to treatment. 
The mainstay of treatment for wet AMD is chronic treatment with anti-VEGF drugs, 
with regular, ongoing clinical review from the point of diagnosis. Given the rapidly 
aging population and constrained health care budgets, there is an unmet need for a 
more cost effective treatment, and one that does not involve such an intensive treat-
ment regimen.
Wet AMD is characterized by the growth of abnormal new blood vessels in a 
process called choroidal neovascularization. These vessels originate from the chorio-
capillaris, and traverse Bruch’s membrane into the sub-retinal pigment epithelial and 
sub-retinal spaces. The new vessels have poor structural integrity and tend to leak, 
resulting in hemorrhage and edema, which results in degradation of visual function. 
This process is often irreversible, leading to scarring and ultimately permanent loss 
of central vision.
At present, the main strategy for the treatment of wet AMD is via modulators of VEGF.4 
There are several anti-VEGF drugs available, including pegaptanib, ranibizumab, beva-
cizumab, and aflibercept. Pivotal studies demonstrated significant visual improvements 
using ranibizumab, given on a monthly basis.5,6 The Comparison of AMD Treatments Tri-
als (CATT) study, analyzing visual outcomes with bevacizumab and ranibizumab therapy, 
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found no significant difference between the two agents at 
1 and 2 years, when given at the same dosing regimen. 
Additionally, both agents showed better visual outcomes 
when administered monthly, compared with “as required” 
(pro re nata [PRN]) dosing.7,8 Monthly dosing imposes a 
significant economic and personal burden on the health care 
sectors and patients respectively, and therefore a less inten-
sive treatment modality would be desirable. Furthermore, 
each injection carries small risks, such as endophthalmitis 
and retinal detachment, and therefore a reduction in their 
frequency, without compromising efficacy, would be a 
substantial advance.9
Radiation and neovascular AMD
Radiation is defined as the outward emission of energy from 
a central source and is commonly used in medical practice. 
Most commonly, it is used as a diagnostic tool, for example 
with plain radiographs and computed tomography. Secondly, 
radioactive substances can be introduced inside the body and 
their release of radiation used for therapeutic purposes such 
as radioisotope treatment of hyperthyroidism. Additionally, 
high powered X-ray machines or radioactive sources can be 
used to deliver radiotherapy when they are aimed into the 
body from an external source.
Radiation is used to selectively and irreversibly damage 
the DNA of target cells which prevents further replication. 
Cells that are rapidly dividing, or of abnormal morphology, 
undergo apoptosis following radiation therapy, whereas 
non-dividing cells are better able to repair the damage and 
remain structurally intact.10
Treatment with radiation can be divided into two catego-
ries. Brachytherapy, known as internal radiotherapy, refers 
to a radiation source being directly inserted or placed next 
to the target site surgically, for example in the treatment of 
prostate tumors.11,12 Teletherapy uses an external source to 
channel radiation into a fine beam that is projected to the 
target tissue. Teletherapy is commonly utilized in oncology, 
particularly with breast malignancy.13 One form of tele-
therapy is stereotactic radiotherapy (SRT), where multiple 
narrow beams of radiation can be used to target small well 
defined areas with precision.
Some radioactive sources, for example potassium-40 
and strontium-90, emit high-speed electrons or positrons 
in a process called beta decay. The potential benefit of beta 
decay in ophthalmology was predicted in animal models in 
1987, when cultured monkey ocular fibroblasts were shown 
to undergo rapidly reduced proliferation following exposure 
in vitro.14 Since then, there have been reports of radiation 
used as an adjunctive treatment for pterygium and glaucoma 
filtration surgery.10,15
Radiation can also be used to treat wet AMD, since 
this disease is caused by abnormal cell proliferation and 
radiation preferentially damages these cells.16–19 However, 
the introduction of anti-VEGF therapy produced better visual 
outcomes than radiation and therefore the use of radiation 
diminished.5,20 Studies are now investigating whether radia-
tion might have a role as an adjuvant to anti-VEGF therapy. 
This adjuvant approach is supported by results in other 
branches of medicine, where combined treatment produces 
better results than either treatment modality individually, 
for example alongside chemotherapy in breast cancer.21 
Anti-VEGF agents have a rapid onset of action, but they 
typically require long-term, repeated dosing to maintain their 
therapeutic effect. As radiotherapy has a delayed effect, but 
a long duration of action, it may work synergistically with 
anti-VEGF therapy.
Epimacular brachytherapy
Epimacular brachytherapy (EMB) was designed as a way 
of precisely delivering radiation to the macula in patients 
with wet AMD.22 The EMB device (NeoVista Inc., Fremont, 
CA, USA) contained a strontium-90/yttrium-90 source that 
delivered radiation to the macula using an intraocular probe 
during vitrectomy. The Macular Epiretinal Brachytherapy in 
Treated Age-related Macular Degeneration (MERITAGE) 
study was an international, multicenter, prospective, inter-
ventional, non-controlled clinical trial of 53 patients with 
previously treated, active disease. All patients underwent 
vitrectomy with EMB, and received PRN ranibizumab 
treatment, governed by pre-defined retreatment criteria. At 
1 year follow-up, 81% of participants lost fewer than 15 Early 
Treatment of Diabetic Retinopathy Study (ETDRS) letters 
whilst only 3.49 anti-VEGF retreatments were required.23 
Secondary outcomes showed a mean best corrected visual 
acuity change of -4.0 ETDRS letters and a small increase 
in optical coherence tomography central retinal thickness of 
50 μm, that failed to reach significance. Subgroup analysis 
revealed that predominantly classic lesions did best, with 
a mean gain of 1.5 ETDRS letters and mean center point 
thickness decreased by 43 μm.24 The 2-year data on the same 
cohort showed more frequent ranibizumab retreatment than in 
year 1, increasing from 0.29 injections per month in months 
0–12, to 0.44 injections per month in months 13–24, however 
both were less than occurred pre-radiation (0.50 injections 
per month).25 Two participants developed possible non-
proliferative radiation retinopathy over 24-month follow-up, 
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but this did not negatively affect their vision. There were no 
other adverse events attributed to radiation therapy.25
The Choroidal Neovascularization Secondary to AMD 
Treated with Beta Radiation Epiretinal Therapy (CABER-
NET) trial was a large, pivotal, multicenter, randomized 
controlled trial investigating the use of EMB in 495 treatment 
naïve patients. At 24 months, 77% and 90% of the EMB 
group and control group lost fewer than 15 ETDRS letters 
respectively. As such the trial failed to meet its non-inferiority 
endpoint. Furthermore, 16% of the EMB group versus (vs) 
26% of the control group gained more than 15 letters. There 
was a reduction in the number of injections in the EMB group, 
at 6.2, compared to 10.4 in the control group, although this 
comparison did not necessarily indicate a reduced demand 
for anti-VEGF therapy in the radiation arm, as this arm had 
fewer mandated injections. Although 3% of the EMB group 
had mild non-proliferative radiation retinopathy, all these 
cases lost fewer than 15 ETDRS letters with a mean gain 
of 4.4 letters at 24 months. Further, the radiation changes 
were often relatively subtle, and substantially different to 
the clinical picture observed with high dose radiation for 
ocular tumors. The participants with retinopathy had better 
outcomes than those who did not, and overall safety was 
deemed acceptable.26,27
In summary, the encouraging early clinical trials of 
EMB for treatment naïve disease were not replicated in a 
Phase III pivotal trial (CABERNET), and therefore its use 
in this setting is unproven.28 A pivotal study in previously 
treated disease (MERLOT; ClinicalTrials.gov identifier 
NCT01006538) is expected to report soon.
SRT
introduction
In order to improve the delivery of radiation to the neovas-
cular lesion, a US biotechnology company (Oraya Therapeu-
tics, Newark, CA, USA) developed an SRT device (IRay) 
designed specifically to treat wet AMD in a single treatment 
session. The device uses low-voltage X-rays to generate 
three separate beams of highly collimated radiation that pass 
through the inferior sclera at different angles to overlap at 
the macula in a 4 mm diameter treatment zone (Figures 1 
and 2). This is designed to minimize the radiation exposure 
to surrounding healthy tissue, whilst giving a high dose 
to the desired target. Unlike EMB, SRT does not require 
vitrectomy and therefore gives a more practical method for 
radiation delivery. Additionally, this may be advantageous 
as vitrectomy reduces the half-life of intravitreal drugs, so 
that any remaining disease activity may be hard to control 
with anti-VEGF agents.29 Furthermore, with IRay, the entire 
4 mm treatment zone receives 90% of the intended dose, 
whereas with EMB the dose declines exponentially with 
distance from the source, meaning larger lesions received 
lower doses peripherally.30
Details of the procedure
The SRT machine is an outpatient radiotherapy platform that 
measures approximately 1.5 meters ×2 meters and is designed 
for use in a standard medical office, without the need for 
added room radiation shielding (Figure 3).31,32 The clinician 
is separated from the patient and protected from radiation by 
a lead screen. Due to the focused nature of the low-energy 
beams, no intrinsic radiation protection such as lead aprons 
are required for the patient or operator.33 The machine has a 
number of key components in order to accurately and safely 
Figure 1 Diagram showing the location of three collimated beams of radiation passing 
through the inferior sclera (green circles) to avoid the crystalline lens, during stereotactic 
radiotherapy.
Note: image courtesy of Oraya (Oraya Therapeutics, Newark, CA, USA).
Figure 2 illustration to show the attenuation effect of the three collimated beams 
to deliver 90% of the desired radiation dose to a 4 mm diameter at the macula.
Notes: Outside the 4 mm diameter zone, the radiation delivered diminishes rapidly. 
Image reproduced with modification, courtesy of Oraya (Oraya Therapeutics, 
Newark, CA, USA).
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deliver treatment. A low energy X-ray tube produces three 
narrow collimated beams, which are designed to pass through 
the inferior sclera, avoiding the crystalline lens, and focus on 
the macula. Built-in computer software is used to robotically 
position the treatment based on the axial length of the eye 
that is entered into the machine by the clinician.
The patient sits normally with their chin placed on a chin 
rest in order to receive the treatment. A sterile, disposable 
contact lens is placed centrally on the cornea and sclera, 
and kept in place by a light suction mechanism (Figure 4). 
A small retractor is used to retract the lower eyelid and 
expose the inferior sclera to the radiation beams. The radia-
tion delivery then commences and treatment usually takes 
approximately 10 minutes. The machine uses an eye tracking 
device to continuously monitor the eye position, and radia-
tion treatment is automatically shut down if excessive eye 
movement is detected.
Efficacy
Two Phase I studies were carried out to assess the safety and 
preliminary efficacy of different doses of SRT.34,35 Radiation 
doses of 16 Gy and 24 Gy in conjunction with ranibizumab 
produced improvement in visual acuity at 6 months. There were 
no safety concerns, and in particular no cases of radiation retin-
opathy, although follow-up was only reported at 6 months.
Following on from the promising Phase I study results, 
the multicenter, randomized, double-masked, sham-controlled 
IRay plus Anti-VEGF Treatment For Patients with Wet 
AMD (INTREPID) trial investigated the use of SRT for 
previously treated wet AMD (ClinicalTrials.gov identifier 
NCT01016873).36 A total of 230 patients were randomized 
2:1:2:1 to 16 Gy, sham 16 Gy, 24 Gy, or sham 24 Gy – all arms 
received PRN ranibizumab based on pre-defined retreatment 
criteria. At 1 year follow-up, both the SRT groups (16 Gy and 
24 Gy) received significantly fewer ranibizumab injections 
than the sham arms (2.64, 2.43 and 3.74 respectively), thus 
meeting the study’s primary end point.36 The effect on reduc-
tion of number of injections was sustained at 2 years (4.5, 5.4 
and 6.6 respectively) with statistical significance for the 16 Gy 
group (P=0.008). Also, 15% of those receiving SRT required 
no further ranibizumab injections over 2 years.37
The 16 Gy, 24 Gy, and sham arms gained 0 or more let-
ters in 32%, 43%, and 38% of eyes respectively, with 68%, 
75%, and 79% losing fewer than 15 letters, respectively at 
24 months. A pre-defined year 1 subgroup analysis showed 
SRT was more effective in lesions 4 mm in greatest lin-
ear dimension, which correlates with the 4 mm diameter 
treatment zone. Those with macular volumes greater than 
the median value of 7.4 mm3 also had better outcomes with 
radiotherapy. The presence of both a greatest linear dimen-
sion 4 mm and a macular volume 7.4 mm3 was associ-
ated with a 55% reduction in the number of ranibizumab 
injections compared to sham (2.08 vs 4.60; P=0.0002), 
better visual outcome (2.18 vs –3.15 letters; P=0.0284) and 
superior structural outcome (-122.6 μm vs -51.5 μm reduc-
tion in mean central subfield thickness on optical coherence 
tomography; P=0.027).38
Based on these subgroup analyses it seems reasonable to 
use this device only when the patient has significant active 
leakage, and to avoid any patient whose lesion extends beyond 
the 4 mm treatment zone, which is centered at the fovea.
Strengths of the INTREPID study are its randomized, 
double-masked, sham-controlled design. Weaknesses include 
the fact that it was not designed to establish efficacy beyond 
year 1; the visits at year 2 and 3 were designed to assess 
safety. After year 1 the anti-VEGF treatment was dictated 
Figure 3 The room set-up of the iRay system.
Notes: The operator controls (left) are separated from the radiotherapy machine 
(right) and patient by a lead-lined glass screen, allowing the operator to view the 
patient. image courtesy of Oraya (Oraya Therapeutics, Newark, CA, USA).
Figure 4 A contact lens, with light suction mechanism, is used to keep the eye in 
position during treatment.
Note: Copyright © 2011. Petrarca R, Jackson TL. Radiation therapy for neovascular 
age-related macular degeneration. Clin Ophthalmol. 2011;5:57–63.22
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by the prevailing standard of care across a range of sites and 
countries. The study was designed to determine if radio-
therapy reduces the number of injections, and not to detect 
a difference in visual acuity outcomes.
Safety
In terms of safety, over 24 months, there were similar numbers 
of adverse events and serious adverse events in both arms. 
Eighteen participants in the radiotherapy arms were identified 
as having microvascular abnormalities (MVAs) by a panel 
of experts, of which two were considered likely to have 
affected vision. These two cases lost 46 letters and 41 letters 
respectively, with 13 and eight PRN ranibizumab injections 
needed respectively, but it was concluded that the underlying 
AMD process was likely to have been the main contributor to 
visual loss in each case. All other 16 cases had MVAs which 
were extra-foveal, and ten of these were located outside the 
4 mm treatment area. Overall, the mean visual change in 
the 18 eyes with radiation attributed MVAs was similar to 
the mean change in the total cohort receiving SRT.37
Conclusion
The clinical, financial, and social burden of AMD is sub-
stantial, and continues to rise with an aging population. It is 
therefore important to explore novel treatment options for the 
expanding cohort of patients undergoing regular intravitreal 
injections. Radiation has many theoretical advantages as a 
means of treating wet AMD, and following the encouraging 
results of INTREPID, a large randomized, double-masked, 
sham-controlled clinical trial is underway (STAR). Like 
INTREPID, the STAR study is designed to establish if SRT 
reduces the number of anti-VEGF injections that patients 
require, but it targets the best responder group identified in 
the INTREPID subgroup analysis. Unlike INTREPID, STAR 
is powered to determine if visual acuity is non-inferior to 
anti-VEGF monotherapy, and with extended safety follow-up 
over 4 years (ClinicalTrials.gov identifier NCT02243878).
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